Patents by Inventor Bjoern Chapuy

Bjoern Chapuy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11446309
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 20, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen
  • Publication number: 20210100813
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Application
    Filed: July 16, 2020
    Publication date: April 8, 2021
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok Kin Wong, Zhao Chen
  • Publication number: 20190292602
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of DLBCL. In particular, the instant disclosure provides a DLBCL classifier that has identified at least five distinct classes of DLBCL cancer, each of which possesses distinct pathogenic mechanisms and outcomes. The instant classifier identifies preferred therapeutic options (including combination therapies) for each such class of DLBCL cancer.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 26, 2019
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Bjoern Chapuy, Margaret Shipp, Chip Stewart, Andrew Dunford, Gad Getz
  • Patent number: 9890429
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 13, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub
  • Publication number: 20170029904
    Abstract: Methods for diagnosing Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) based on a diagnostic score, as well as determining MYC activity levels and selecting treatments based on a MYC activity score.
    Type: Application
    Filed: April 7, 2015
    Publication date: February 2, 2017
    Inventors: Scott J. Rodig, Christopher Daniel Carey, Margaret A. Shipp, Stefano Monti, Daniel Gusenleitner, Bjoern Chapuy
  • Publication number: 20160279141
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 29, 2016
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen
  • Publication number: 20150004158
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 1, 2015
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub